The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IV.c

Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

Publications

Bruguera-Àvila N, Sánchez-Martínez E, Garcia-Olivé I, Pérez-Ochoa JF, Martínez-Barenys C, Ruiz-Manzano J

Obliterating bronchiolitis in a patient treated with (D)-penicillamine.

Archivos de bronconeumologia. 2013;49(9):411-2

Devouassoux G, Cottin V, Lioté H, Marchand E, Frachon I, Schuller A, Béjui-Thivolet F, Cordier JF, Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P)

Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis.

The European respiratory journal. 2009;33(5):1053-61

Alekperov RT, Avdeev SN, Kotovskaia MA

[Obliterating bronchiolitis induced by D-penicillamine in the female patient with systemic scleroderma].

Terapevticheskii arkhiv. 2004;76(3):74-6

Boehler A, Vogt P, Speich R, Weder W, Russi EW

Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine.

The European respiratory journal. 1996;9(6):1317-9

Padley SP, Adler BD, Hansell DM, Müller NL

Bronchiolitis obliterans: high resolution CT findings and correlation with pulmonary function tests.

Clinical radiology. 1993;47(4):236-40

Penny WJ, Knight RK, Rees AM, Thomas AL, Smith AP

Obliterative bronchiolitis in rheumatoid arthritis.

Annals of the rheumatic diseases. 1982;41(5):469-72

Camus P

[The respiratory complications of D-Penicillamine therapy (author's transl)].

Revue francaise des maladies respiratoires. 1982;10(1):7-20

Wolfe F, Schurle DR, Lin JJ, Polland SM, Smith TW, Montgomery-Short R, James DL

Upper and lower airway disease in penicillamine treated patients with rheumatoid arthritis.

The Journal of rheumatology. 1983;10(3):406-10

Stein HB, Chalmers A, Schroeder ML, Dillon A

Selected adverse reactions of D-penicillamine.

Clinical and investigative medicine. Medecine clinique et experimentale. 1984;7(1):73-6

van de Laar MA, Westermann CJ, Wagenaar SS, Dinant HJ

Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans.

Arthritis and rheumatism. 1985;28(1):93-7

Amin-Zaki L, Al-Damluji S

D-penicillamine and obliterative bronchiolitis.

British medical journal. 1977;1(6062):713

Epler GR, Snider GL, Gaensler EA, Cathcart ES, FitzGerald MX, Carrington CB

Bronchiolitis and bronchitis in connective tissue disease. A possible relationship to the use of penicillamine.

JAMA. 1979;242(6):528-32